Vortex Brands Co. (VTXB)

OTCMKTS · Delayed Price · Currency is USD

0.0002

+0.0001 (50.00%)

Aug 1, 2025, 3:36 PM EDT

Inozyme Pharma Income Statement

Financials in millions USD. Fiscal year is March - February.

Millions USD. Fiscal year is Mar - Feb.

Fiscal Year	FY 2022	FY 2021	FY 2020	FY 2018
Period Ending	Feb '22 Feb 28, 2022	Feb '21 Feb 28, 2021	Feb '20 Feb 29, 2020	Feb '18 Feb 28, 2018
Revenue	0.06	-	-	-
Cost of Revenue	0.02	-	-	-
Gross Profit	0.04	-	-	-
Selling, General & Admin	0.42	0.21	0.36	0.15
Research & Development	-	-	0.07	0.05
Operating Expenses	0.48	0.22	0.44	0.2
Operating Income	-0.44	-0.22	-0.44	-0.2
Other Non Operating Income (Expenses)	0	-	-	-
EBT Excluding Unusual Items	-0.44	-0.22	-0.44	-0.2
Gain (Loss) on Sale of Investments	-0.01	-	-	-
Pretax Income	-0.44	-0.22	-0.44	-0.2
Net Income	-0.44	-0.22	-0.44	-0.2
Net Income to Common	-0.44	-0.22	-0.44	-0.2
Shares Outstanding (Basic)	285	263	235	57
Shares Outstanding (Diluted)	285	263	235	57
Shares Change (YoY)	8.33%	11.91%	313.36%	-
EPS (Basic)	-0.00	-0.00	-0.00	-
EPS (Diluted)	-0.00	-0.00	-0.00	-
Free Cash Flow	-0.42	0	-0.22	-0.76
Free Cash Flow Per Share	-0.00	-	-0.00	-0.01
Dividend Per Share	0.000	-	-	-
Gross Margin	69.57%	-	-	-
Operating Margin	-789.10%	-	-	-
Profit Margin	-800.50%	-	-	-
Free Cash Flow Margin	-751.27%	-	-	-
EBITDA	-0.38	-0.21	-0.43	-0.19
D&A For EBITDA	0.06	0.01	0.01	0.01
EBIT	-0.44	-0.22	-0.44	-0.2

Updated Oct 13, 2022. Source: S&P Global Market Intelligence. Standard template. Financial Sources.